- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03471182
Investigation of Cocaine Addiction Using mGluR5 PET and fMRI
Study Overview
Status
Conditions
Detailed Description
Cocaine use disorder (CUD) remains a significant public health concern that is resistant to current treatments. Challenges to treating CUD include an imbalance in neurobiological systems that 're-wire' the brain such that appetitive and habitual processes influence decision-making and behavior. This research project aims to provide insight into this reorganized circuitry in CUD by investigating neurofunctional systems related to glutamatergic plasticity and functional brain networks during initial (2-5 days) abstinence. To target this potentially critical period of recovery, currently-using and non-treatment-seeking individuals with CUD will undergo a cocaine self-administration paradigm 2-5 days prior to completing [18F]FPEB positron emission tomography (PET) and functional magnetic resonance imaging (fMRI). Healthy comparison (HC) subjects that have participated in [18F]FPEB PET as part of other Yale approved protocols will be recruited to participate in the fMRI portion of this study.
Aim 1: To determine the availability of mGluR5 using [18F]FPEB PET during initial abstinence in individuals with CUD. The investigators hypothesize individuals with CUD, relative to HC, will exhibit concurrently and regionally specific increases (e.g., in the striatum) and decreases (e.g., in the prefrontal cortex) in mGluR5 availability.
Aim 2: To determine patterns of resting-state, response-inhibition, an automaticity related connectivity within and between large-scale functional networks using fMRI during initial abstinence in individuals with CUD. The investigators hypothesize network-based analyses of fMRI will reveal lower frontoparietal and greater limbic network modulation in CUD as compared to HC.
Aim 3: To explore the relationships between mGluR5 availability and functional network activity during initial abstinence in individuals with CUD. The investigators will perform multi-modal analysis of PET and fMRI data to examine links between molecular and functional systems in CUD using emerging 'fusion' approaches. While exploratory in nature, the investigators expect to find links between alterations in mGluR5 systems and functional reorganization in CUD (e.g., greater dorsostriatal mGluR5 may be linked to blunted frontoparietal inhibition).
Aim 4: To explore the relationships between mGluR5 availability, functional network activity (and their linkages) with cocaine self-administration, disease severity and chronicity, and psychometric assessments of impulsivity and compulsivity. While exploratory in nature, the investigators expect more substantial neurofunctional alterations during initial abstinence will be associated with greater cocaine self-administration, disease severity, impulsivity and compulsivity in individuals with CUD.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jessica Costeines, MA
- Phone Number: 203-974-7559
- Email: jessica.costeines@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Connecticut Mental Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All participants:
- Age 21 - 60 years
- Provide voluntary, written, informed consent
- Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations
- For females: non-lactating, no longer of child-bearing potential or agreeing to practice effective contraception during the study (e.g., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device [IUD] or intrauterine system [IUS]; barrier methods: condom or occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository; male partner sterilization; true abstinence when this is in line with the preferred and usual lifestyle of the subject), and a negative serum pregnancy test
Participants with a cocaine use disorder:
- DSM-5 criteria for moderate or severe cocaine-use disorder
- Recent street cocaine use in excess of quantities used in the current study
- Intravenous and/or smoked (crack/freebase) cocaine use
- Positive urine toxicology screen for cocaine
Healthy comparison participants:
- Successful completion of an [18F]FPEB scan as part of another Yale approved protocol as a healthy control/comparison subject
Exclusion Criteria:
All participants:
- Any condition that, in the opinion of investigators, would prevent compliance with the study protocol
- A history of significant medical or neurological illness (e.g., coronary artery disease, significant anemia, seizures)
- Current use of psychotropic and/or potentially psychoactive medications
- Physical or laboratory evidence of pregnancy
- Meet any additional PET/MR imaging-related exclusion criteria, including:
- Presence of MRI incompatible implants and other contraindications for MRI (e.g., pacemaker, artificial joints, non-removable body piercings, etc.)
- Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the participant to exceed the yearly dose limits
- History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).
- Claustrophobia
- Severe motor problems that prevent the subject from lying still for PET/MR imaging
- Complaints of chronic pain (e.g., as the result of rheumatoid arthritis)
- Current, past or anticipated exposure to radiation in the work place
Participants with a cocaine use disorder:
- Other drug use disorder (except for tobacco-use disorder)
- Less than 1 year of cocaine use disorder
- A DSM-5 major psychiatric diagnosis (schizophrenia, bipolar disorder, etc.) unrelated to cocaine
Healthy comparison participants:
- Any DSM-5 major psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), except tobacco-use disorder
- Positive drug screen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Psychiatric and Cognitive Testing
All participants will complete psychiatric assessment and cognitive testing.
|
Interviews, questionnaires, and computer testing.
|
Active Comparator: Cocaine Self-adminstration
This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
|
The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
Other Names:
|
Active Comparator: Positron Emission Tomography
All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
|
PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available.
Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling.
A radial artery catheter may also be inserted by an experienced physician before the PET scan.
At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction.
PET scans will be acquired using bolus or bolus plus constant infusion administration of [18F]FPEB.
Other Names:
|
Active Comparator: Magnetic Resonance Imaging
All participants will complete one MRI scan to assess brain structure and function.
|
Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center.
High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure.
Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences.
Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regional Availability of Metabotropic Glutamate Type-5 Receptors (mGluR5)
Time Frame: Following 2-5 days of cocaine abstinence
|
Receptor availability assessed as the volume of distribution (VT) of [18F]FPEB radiotracer, measured using positron emission tomography (PET).
Higher [18F]FPEB VT values indicate a greater availability of mGluR5 receptors.
|
Following 2-5 days of cocaine abstinence
|
Functional Brain Network Engagement Associated With Response Inhibition
Time Frame: Following 2-5 days of cocaine abstinence.
|
Independent component analysis (ICA) of functional MRI data separates brain activity associated with distinct functional networks.
Comparing the activity in these networks to the fMRI task events using a regression analysis produces a beta-weight where a larger beta indicates the network was more activated or 'engaged' in processing the task demands.
In this study, participants completed a Go/NoGo task to assess brain processing associated with infrequent-stimulus response inhibition (i.e., correct NoGo's) compared to frequent-stimulus responses (i.e., correct Go's).
|
Following 2-5 days of cocaine abstinence.
|
Resting-state Functional Brain Network Activity, Fractional Amplitude of Low-frequency Fluctuations (fALFF)
Time Frame: Following 2-5 days of cocaine abstinence.
|
Independent component analysis (ICA) of functional MRI data separates brain activity associated with distinct functional networks.
The fractional amplitude of low-frequency fluctuations (fALFF) during resting-state reflects a measure of the general health status of a network, comprised of both the strength of network activity and within-network connectivity absent of any specific cognitive demands.
|
Following 2-5 days of cocaine abstinence.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain activity patterns
Time Frame: Within 2-5 days of self-administration in cocaine participants; within 5 days of PET as possible for healthy comparison participants
|
Brain activity patterns as measured during task-based and resting-state fMRI
|
Within 2-5 days of self-administration in cocaine participants; within 5 days of PET as possible for healthy comparison participants
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Patrick Worhunsky, PhD, Assistant Professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Compulsive Behavior
- Impulsive Behavior
- Behavior, Addictive
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Anesthetics, Local
- Dopamine Uptake Inhibitors
- Vasoconstrictor Agents
- Cocaine
Other Study ID Numbers
- 2000021196
- 1K01DA042998-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine Dependence
-
W. Michael HootenNational Institute on Drug Abuse (NIDA)Recruiting
-
University of ArkansasNational Institute on Drug Abuse (NIDA); Baylor College of MedicineCompleted
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)Completed
-
Tong LeeNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedCocaine Dependence | Methamphetamine DependenceUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence | Cocaine Dependence | Methamphetamine DependenceUnited States
-
The University of Texas Health Science Center,...National Institute on Drug Abuse (NIDA)RecruitingAlcohol Dependence | Substance Abuse | Cocaine Dependence | Opiate Dependence | Cocaine AbuseUnited States
-
Johns Hopkins UniversityCompletedBehavior, Addictive | Heroin Dependence | Opioid Dependence | Cocaine Dependence | Cocaine AbuseUnited States
-
Wayne State UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Heroin Dependence | Cocaine Abuse or DependenceUnited States
-
University of PennsylvaniaCompletedCocaine DependenceUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use Disorder | Cocaine Use Disorder | Cocaine Dependence | Methamphetamine Dependence | Stimulant Use Disorder | Methamphetamine Abuse | Cocaine Abuse | Stimulant Abuse | Stimulant UseUnited States
Clinical Trials on Psychiatric and Cognitive Testing
-
Hospital de Clinicas de Porto AlegreRecruitingSpinocerebellar Ataxia Type 3 | Machado-Joseph Disease | SCA3 | MJDBrazil
-
Jennifer SweetNational Institute of Mental Health (NIMH); University Hospitals Cleveland...Suspended
-
Hôpital le VinatierRecruitingSchizophrenia | Alzheimer Disease | Bipolar Disorder | FTDFrance
-
University Hospital, LilleCompleted
-
University of Medicine and Dentistry of New JerseyNational Institute of Mental Health (NIMH)Completed
-
Johannes MichalakCompleted
-
University of California, Los AngelesDanone Nutricia ResearchCompleted
-
Dr. Stephen ChoiActive, not recruitingAutoimmune Diseases | Inflammation | Delirium | Cognitive Impairment | Cognitive Change | Postoperative Cognitive Dysfunction | Mild Cognitive Impairment | Cognitive Decline | Working MemoryCanada
-
University of ZurichEnrolling by invitation
-
Region ÖstergötlandNot yet recruitingCognitive Symptom | Primary Health Care | Mental Health IssueSweden